April 12, 2016
MSD will copromote its anti-PD-1 antibody pembrolizumab with Taiho Pharmaceutical in Japan, hoping to maximize the value of the immuno-oncology drug in a market where it has only one cancer drug among its offerings. Under the deal announced on April...read more